Infliximab Induction Regimen for Moderate to Severe Crohn's Disease

Standard Induction Dosing

• The American Gastroenterological Association and European Crohn's and Colitis Organisation recommend administering infliximab 5 mg/kg intravenously at weeks 0, 2, and 6 for induction therapy in patients with moderate to severe Crohn's disease 1, 2

Combination Therapy Recommendation

• The European Crohn's and Colitis Organisation guidelines provide a strong recommendation for combination therapy with thiopurines when initiating infliximab, based on moderate-quality evidence 1, 2
• The American Gastroenterological Association suggests combination therapy over monotherapy, though notes the evidence certainty is very low; they acknowledge that combination with methotrexate may also be effective based on indirect evidence 3, 4

Response Assessment and Decision Points

• Evaluate clinical response between weeks 8-12 after initiating induction therapy, as recommended by clinical guidelines 6

Clinical Context and Positioning

• The European Crohn's and Colitis Organisation guidelines provide a strong recommendation for TNF inhibitors (infliximab, adalimumab, certolizumab pegol) to induce remission in patients who have not responded to conventional therapy, with moderate-quality evidence 1, 2
• The American Gastroenterological Association recommends infliximab, adalimumab, or ustekinumab over certolizumab pegol for induction in biologic-naïve patients 3, 7

Common Pitfalls to Avoid

• Do not delay combination therapy: starting thiopurines concurrently with infliximab is more effective than adding them later, as this prevents antibody formation from the outset, as recommended by the European Crohn's and Colitis Organisation 1, 2